{"id":502922,"date":"2021-06-10T16:49:06","date_gmt":"2021-06-10T20:49:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/"},"modified":"2021-06-10T16:49:06","modified_gmt":"2021-06-10T20:49:06","slug":"hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/","title":{"rendered":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN FRANCISCO<\/span>, June 10, 2021<\/span> \/PRNewswire\/ —\u00a0Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI)\u00a0investors with significant losses to submit your losses now<\/a>.\u00a0 A securities fraud class action is pending and certain investors may have valuable claims. <\/p>\n

\n

\n
\n \"Hagens
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n\n\n\n\n\n\n
\n

\n
\n Class Period:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Nov. 26, 2019 \u2013 May 6, 2021<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Lead Plaintiff Deadline:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n July 6, 2021<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Visit:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n www.hbsslaw.com\/investor-fraud\/CCXI<\/a>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Contact An Attorney Now: <\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n CCXI@hbsslaw.com<\/a>\u00a0<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n 844-916-0895<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action: <\/b>\n <\/p>\n

The lawsuit focuses on ChemoCentryx’s statements about its new drug application (“NDA”) for its vasculitis drug candidate Avacopan.<\/p>\n

Beginning on Nov. 25, 2019<\/span>, ChemoCentryx touted positive topline data from its Pivotal Phase III ADVOCATE trial demonstrating Avacopan’s superiority over standard of care in ANCA-associated vasculitis and that the trial met both of its primary endpoints.\u00a0 This and subsequent positive announcements sent the price of CCXI soaring.<\/p>\n

The complaint alleges ChemoCentryx concealed that: (1) the trial’s study design was flawed; (2) data from the trial raised serious safety concerns; and (3) these issues presented a substantial concern about the viability of ChemoCentryx’s NDA.<\/p>\n

On May 4, 2021<\/span>, the truth emerged when the FDA announced it had identified several areas of concern, including “uncertainties about the interpretability of the data and the clinical meaningfulness of these results.”\u00a0 In addition, the document took issue with the complex trial design and the lack of long-term safety data.<\/p>\n

This news drove the price of ChemoCentryx shares crashing over 45% lower on May 4, 2021<\/span>, wiping out as much as $1.5 billion<\/span> of the company’s market capitalization.<\/p>\n

“We’re focused on investors’ losses and proving ChemoCentryx misled investors about Avacopan’s efficacy and safety,” said Reed Kathrein<\/span>, the Hagens Berman partner leading the investigation. <\/p>\n

If you are a ChemoCentryx\u00a0investor and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman<\/a>.<\/p>\n

\n Whistleblowers: <\/b>Persons with non-public information regarding ChemoCentryx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. \u00a0Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. \u00a0For more information, call Reed Kathrein<\/span> at 844-916-0895<\/b> or email mailto:<\/a>CCXI@hbsslaw.com<\/a>.<\/p>\n

\n
\n About Hagens Berman <\/a>
\n
\n <\/u>Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.\u00a0 The firm represents investors, whistleblowers, workers and consumers in complex litigation.\u00a0 More about the firm and its successes is located at hbsslaw.com<\/a>. \u00a0For the latest news visit our newsroom<\/a><\/u> or follow us on Twitter at @classactionlaw<\/a><\/u>.<\/p>\n

\n Contact:
<\/u>
\n Reed Kathrein<\/span>, 844-916-0895<\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel-301310479.html<\/a><\/p>\n

SOURCE Hagens Berman Sobol Shapiro LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN FRANCISCO, June 10, 2021 \/PRNewswire\/ —\u00a0Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI)\u00a0investors with significant losses to submit your losses now.\u00a0 A securities fraud class action is pending and certain investors may have valuable claims. Class Period: Nov. 26, 2019 \u2013 May 6, 2021 Lead Plaintiff Deadline: July 6, 2021 Visit: www.hbsslaw.com\/investor-fraud\/CCXI Contact An Attorney Now: CCXI@hbsslaw.com\u00a0 844-916-0895 ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action: The lawsuit focuses on ChemoCentryx’s statements about its new drug application (“NDA”) for its vasculitis drug candidate Avacopan. Beginning on Nov. 25, 2019, ChemoCentryx touted positive topline data from its Pivotal Phase III ADVOCATE trial demonstrating Avacopan’s superiority over standard of care in ANCA-associated vasculitis and that the trial met both of … <\/p>\n

Continue reading “HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-502922","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN FRANCISCO, June 10, 2021 \/PRNewswire\/ —\u00a0Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI)\u00a0investors with significant losses to submit your losses now.\u00a0 A securities fraud class action is pending and certain investors may have valuable claims. Class Period: Nov. 26, 2019 \u2013 May 6, 2021 Lead Plaintiff Deadline: July 6, 2021 Visit: www.hbsslaw.com\/investor-fraud\/CCXI Contact An Attorney Now: CCXI@hbsslaw.com\u00a0 844-916-0895 ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action: The lawsuit focuses on ChemoCentryx’s statements about its new drug application (“NDA”) for its vasculitis drug candidate Avacopan. Beginning on Nov. 25, 2019, ChemoCentryx touted positive topline data from its Pivotal Phase III ADVOCATE trial demonstrating Avacopan’s superiority over standard of care in ANCA-associated vasculitis and that the trial met both of … Continue reading "HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-10T20:49:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/450112\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel\",\"datePublished\":\"2021-06-10T20:49:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/\"},\"wordCount\":460,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/450112\\\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/\",\"name\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/450112\\\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg\",\"datePublished\":\"2021-06-10T20:49:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/450112\\\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/450112\\\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/","og_locale":"en_US","og_type":"article","og_title":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel - Market Newsdesk","og_description":"PR Newswire SAN FRANCISCO, June 10, 2021 \/PRNewswire\/ —\u00a0Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI)\u00a0investors with significant losses to submit your losses now.\u00a0 A securities fraud class action is pending and certain investors may have valuable claims. Class Period: Nov. 26, 2019 \u2013 May 6, 2021 Lead Plaintiff Deadline: July 6, 2021 Visit: www.hbsslaw.com\/investor-fraud\/CCXI Contact An Attorney Now: CCXI@hbsslaw.com\u00a0 844-916-0895 ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action: The lawsuit focuses on ChemoCentryx’s statements about its new drug application (“NDA”) for its vasculitis drug candidate Avacopan. Beginning on Nov. 25, 2019, ChemoCentryx touted positive topline data from its Pivotal Phase III ADVOCATE trial demonstrating Avacopan’s superiority over standard of care in ANCA-associated vasculitis and that the trial met both of … Continue reading \"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-10T20:49:06+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/450112\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel","datePublished":"2021-06-10T20:49:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/"},"wordCount":460,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/450112\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/","name":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/450112\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg","datePublished":"2021-06-10T20:49:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/450112\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/450112\/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-alerts-chemocentryx-ccxi-investors-to-expanded-fraudulent-period-in-securities-fraud-action-investors-should-secure-counsel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/502922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=502922"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/502922\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=502922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=502922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=502922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}